EGFR and non-small cell lung carcinoma: The effectiveness ofEGFR inhibitors in treating patients with EGFR-mutant NSCLC is well modeled in mousexenograft assays, where oral administration of erlotinib for a few days is sufficientto cause massive regression of established tumors.